<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939077</url>
  </required_header>
  <id_info>
    <org_study_id>MR-31-20-000323</org_study_id>
    <nct_id>NCT04939077</nct_id>
  </id_info>
  <brief_title>Treatment of Heart Failure Using Human Umbilical Cord Mesenchymal Stem Cells(hUC-MSC)</brief_title>
  <official_title>Treatment of Heart Failure Using Human Umbilical Cord Mesenchymal Stem Cells(hUC-MSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an exploratory clinical study to observe the improvement of heart function&#xD;
      before and after the treatment by human umbilical cord mesenchymal stem cells, and the&#xD;
      purpose is to evaluate the safety and effectiveness of human umbilical cord mesenchymal stem&#xD;
      cells in the treatment of heart failure. The study is a randomized parallel controlled study.&#xD;
      Patients receive a review of which main content includes symptom improvement, cardiac&#xD;
      function improvement, and adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an exploratory clinical study to observe the improvement of heart function&#xD;
      before and after the treatment by human umbilical cord mesenchymal stem cells, and the&#xD;
      purpose is to evaluate the safety and effectiveness of human umbilical cord mesenchymal stem&#xD;
      cells in the treatment of heart failure. The study is a randomized parallel controlled study.&#xD;
      The research process is as follows: 1. Twenty eligible patients with ischemic heart disease&#xD;
      were recruited, fully informed, and signed a consent form, and randomly divided into CABG&#xD;
      group (n=10) or CABG + stem cell treatment group (n=10); 2. CABG was performed under general&#xD;
      anesthesia in both groups. In the cell therapy group, 1×10^7 human umbilical cord Mesenchymal&#xD;
      Stem Cells were injected to the edge of the myocardial infarction area at 20 points at the&#xD;
      same time in CABG; 3. Use vasoactive drugs and antibiotics to prevent infection one week&#xD;
      after surgery. After the operation, before discharge, 1 month, 3 months, 6 months, 12 months&#xD;
      after discharge, and once a year thereafter, until the death of the patient. Patients receive&#xD;
      a review of which main content includes symptom improvement, cardiac function improvement,&#xD;
      and adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>Day 0, Day 30, Day 90, Day 180, Day 360, Day 720</time_frame>
    <description>The change in Left ventricular ejection fraction (LVEF) % after the operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular end diastolic volume</measure>
    <time_frame>Day 0, Day 30, Day 90, Day 180, Day 360, Day 720</time_frame>
    <description>The change in Left ventricular end diastolic volume (LVEDV) ml after the operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular end systolic volume</measure>
    <time_frame>Day 0, Day 30, Day 90, Day 180, Day 360, Day 720</time_frame>
    <description>The change in Left ventricular end systolic volume (LVESV) ml after the operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke volume</measure>
    <time_frame>Day 0, Day 30, Day 90, Day 180, Day 360, Day 720</time_frame>
    <description>The change in Stroke volume (SV) ml after the operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular apex four-chamber end systolic diameter</measure>
    <time_frame>Day 0, Day 30, Day 90, Day 180, Day 360, Day 720</time_frame>
    <description>The change in Left ventricular apex four-chamber end systolic diameter (LVESD) mm after the operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 minutes walking distance</measure>
    <time_frame>Day 0, Day 30, Day 90, Day 180, Day 360, Day 720</time_frame>
    <description>The change in 6 minutes walking distance m after the operation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>THE WORLD HEALTH ORGANIZATION QUALITY OF LIFE (WHOQOL) -BREF</measure>
    <time_frame>Day 0, Day 30, Day 90, Day 180, Day 360, Day 720</time_frame>
    <description>The change in THE WORLD HEALTH ORGANIZATION QUALITY OF LIFE (WHOQOL) -BREF after the operation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Myocardial Ischemia</condition>
  <condition>Ventricular Dysfunction, Left</condition>
  <arm_group>
    <arm_group_label>CABG with hUC-MSC treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the CABG with hUC-MSC treatment group, 1×10^7 human umbilical cord Mesenchymal Stem Cells were injected to the edge of the myocardial infarction area at 20 points at the same time in CABG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>CABG was performed under general anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Human Umbilical Cord Mesenchymal Stem Cells</intervention_name>
    <description>In CABG with hUC-MSC treatment group, 1×10^7 Human Umbilical Cord Mesenchymal Stem Cells were injected at the edge of the myocardial infarction area at 20 points at the same time in CABG</description>
    <arm_group_label>CABG with hUC-MSC treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patients with coronary heart disease, the effect of drug treatment is not good,&#xD;
             and the clinical manifestations of left ventricular insufficiency occur, EF&lt;40%;&#xD;
&#xD;
          -  Coronary angiography confirmed that there is a chronic occlusive disease of the&#xD;
             coronary artery, which is manifested as severe stenosis of single or multiple coronary&#xD;
             vessels (≥75%), or even complete occlusion;&#xD;
&#xD;
          -  After the doctor explained the treatment process and possible toxic and side effects,&#xD;
             he was willing to treat and agreed to cooperate in the observation of the efficacy.&#xD;
             But patients can withdraw from clinical trials and long-term follow-up observation at&#xD;
             any time and unconditionally;&#xD;
&#xD;
          -  The patient has no mental illness and language dysfunction and can fully understand&#xD;
             the treatment method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Does not meet the above selection criteria;&#xD;
&#xD;
          -  Unable to sign the informed consent form, unable to comply with the agreed timetable&#xD;
             of this study;&#xD;
&#xD;
          -  There are reasons to suspect that the patient was forced to join the trial;&#xD;
&#xD;
          -  Acute left ventricular insufficiency, cardiogenic shock;&#xD;
&#xD;
          -  The patient has any infectious diseases (including bacterial and viral infections);&#xD;
&#xD;
          -  Others who are clinically considered unsuitable for this treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongmin Liu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital, Shanghai Tongji University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhongmin Liu, Doctor</last_name>
    <phone>+86-021-38804518</phone>
    <email>liu.zhongmin@tongji.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai East Hospital, Shanghai Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongmin Liu, Doctor</last_name>
      <phone>+86-021-38804518</phone>
      <email>liu.zhongmin@tongji.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Umbilical Cord Mesenchymal Stem Cells</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

